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Abstract
Background
Micro-crystals of calcium phosphate have been detected on the aortic valve of patients with
aortic stenosis using scanning electron microscopy. It is not known whether crystalisation is
specific to heart valve tissue or a general blood-derived process.
Methods
To this end we modified the method to determine whether calcium phosphate micro-crystals
were present in the blood of patients with aortic stenosis. The method was first validated by
adding synthetic calcium phosphate hydroxyapatite micro-crystals to healthy volunteer
blood samples and determining the lower limit of detection. Then the method was used to
examine the blood of 63 patients with echocardiographically confirmed aortic stenosis and
69 unaffected controls undergoing echocardiography for other reasons. Serum calcium and
phosphate were measured and the calcium phosphate product compared in cases and
controls.
Results
In the validation study, synthetic hydroxyapatite micro-crystals were identified down to a
lower concentration limit of 0.008mg/mL. In the experimental study no particles were identi-
fied in any patient, with or without aortic stenosis, even though serum calcium phosphate
was higher in cases compared with controls 2.6mmol/L (2.58–2.77) versus 2.47mmol/L
(2.36–2.57), p = 0.005 for the difference.
Conclusion
The results of our study confirm a positive association between serum calcium phosphate
and aortic stenosis, but indicate that the calcium phosphate particles found in valve tissue
do not precipitate freely in the blood.
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Introduction
Aortic stenosis is a serious heart valve disorder affecting about 12% of people over the age of
75 [1]. It is caused by progressive deposition of calcified material on the aortic valve, leading to
valve leaflet restriction and obstruction of blood flow from the heart. Death follows symptoms
of cardiac insufficiency in the majority of cases, unless the aortic valve is surgically replaced.
Progression from mild to severe disease occurs in most affected individuals, but the rate of
progression varies widely; on average it is about 5 years [2]. There is no means of prevention.
Scanning electron microscopy has demonstrated micro-particles of calcified material on
the aortic valve consisting of a highly crystalline form of calcium phosphate hydroxyapatite,
distinct from bone mineral [3]. Whilst the number and density of micro-crystals increases
with disease severity, the same fundamental particle is present at all stages of disease, from
mild to severe aortic stenosis [3].
It is not known whether calcium phosphate micro-crystals are present in the blood of
patients with aortic stenosis, and therefore whether precipitation is a general blood-derived
process or specific to heart valve tissue. If present in the blood, their measurement would pro-
vide a potential means of screening for the disorder or identifying a group of patients at risk of
rapid progression who may need earlier valve replacement.
We sought to apply the method for imaging calcium phosphate micro-crystals on aortic
valve tissue to the blood of patients with and without aortic stenosis, to determine whether
micro-crystals were present.
Methods
Between July 2016 and January 2017, 63 consecutive patients with echocardiographically con-
firmed aortic stenosis were identified, from cardiology clinics and wards at Barts Heart Centre,
London. Aortic stenosis was defined as thickened aortic valve leaflets with a peak trans-aortic
velocity greater than or equal to 2m/s. We excluded patients with bicuspid aortic valve (5) or
rheumatic valve disease (4). A further 69 patients, without aortic stenosis, who were undergo-
ing echocardiography for other reasons, were invited to participate in the study as unaffected
controls. Patients gave their written consent to participate in the study which was approved by
the North West Preston Research Ethics Committee.
The method used for imaging calcification, by scanning electron microscopy in valvular tis-
sue has been described [3]. The method was modified to detect micro-crystals in blood. A vali-
dation study was conducted on multiple blood samples from a healthy volunteer to which we
added, across a range of concentrations, synthetic calcium phosphate hydroxyapatite micro-
crystals (Sigma-Aldrich hydroxyapatite nanopowder 693863-5G) to determine the lower limit
of detection by scanning electron microscopy. We started with a concentration of 0.5mg/mL,
confirmed that the crystals were present and undertook sequential step-down dilutions
(0.1mg/mL, 0.05mg/mL etc) until the crystals were no longer detectable and then stepped up
in smaller concentration increments until they were once again detectable. The synthetic
micro-crystals were similar in composition (95% hydroxyapatite), morphology (round), den-
sity (3.1g/mL) and size (200nm) to the particles found in aortic stenosis [3]. The samples were
centrifuged at 1000g for 10 minutes, to separate red blood cells and hydroxyapatite micro-crys-
tals from other blood components. Red blood cells mixed with micro-crystals were transferred
to a new flask and centrifuged at 3600g. An aliquot of 5μL was extracted from the bottom of
the flask, containing red blood cells plus micro-crystals, placed on a microscope slide and air-
dried overnight. Once dried, the samples were coated with carbon using a Quorum K975X
Carbon coater and imaged under a Hitachi S-3400N or Carl Zeiss Leo scanning electron
microscope, using a voltage of 10kV. The backscattered electron mode was used to identify
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hydroxyapatite micro-crystals on the slide. This same method was applied to blood samples
from patients affected with aortic stenosis and blood samples from the unaffected control
group.
Peripheral blood samples were also collected for serum phosphate concentrations using the
colorimetric reaction method with ammonium molybdate [4], and for total calcium, using
indirect potentiometry [5]. Biochemical analyses were performed “blind”, that is without
knowledge of which samples were cases or controls. Serum phosphate, serum calcium and the
calculated calcium—phosphate product (an independent risk factor for aortic stenosis and tar-
get for treatment) [6] were compared using unpaired t-tests. Stata was used for all analyses.
Results
Table 1 gives clinical and echocardiographic details of the patients with and without aortic ste-
nosis in the study. There were no statistically significant differences between the groups apart
from the expected differences in echocardiographic parameters reflecting the presence or
absence of aortic stenosis in cases and controls respectively.
Table 2 gives the concentrations of serum calcium, serum phosphate and the calcium
phosphate product (with 95% confidence internals), in cases and controls. For serum calcium
these were, respectively, 2.37mmol/L (2.34–2.39) and 2.34mmol/L (2.32–2.37) (p = 0.154
for difference), for serum phosphate, 1.13mmol/L (1.09–1.17) and 1.05mmol/L (1.01–1.10)
(p = 0.011 for difference) and for the calcium phosphate product, 2.67mmol/L (2.58–2.77) and
2.47mmol/L (2.36–2.57), p = 0.005 for the difference.
In the validation study, synthetic hydroxyapatite micro-crystals were identified at a concen-
tration of 0.5mg/mL and at serial step-down concentrations of 0.1mg/mL, 0.05mg/mL,
Table 1. Characteristics of individuals with and without aortic stenosis in the study.
Cases (n = 63) Controls (n = 69) p-value
Age 77 (69–84) 74 (65–81) 0.073
Male 35 (56) 45 (65) 0.288
Smoker 1 (2) 6 (9) 0.118
Medical history
Myocardial infarction 12 (19) 16 (23) 0.357
Stroke 7 (11) 10 (14) 0.376
Renal failure 5 (8) 6 (9) 0.564
Diabetes 19 (30) 16 (23) 0.431
Echocardiographic parameters
Peak trans-aortic velocity (m/s) 3.6 (2.9–4.1) 1.3 (1.1–1.6) <0.001
Peak trans-valvar gradient (mmHg) 48 (32–68) 7.1 (5.4–11) <0.001
Aortic Valve Area (cm2) 0.8 (0.7–1.2) 2.4 (2.0–3.2) <0.001
Values are number (%) except median (IQR)
https://doi.org/10.1371/journal.pone.0202282.t001
Table 2. Serum calcium, serum phosphate and the serum calcium phosphate product in 63 cases of aortic stenosis and 69 controls without aortic stenosis.
Serum level (mmol/L) Mean (95% CI) p-value
Cases, n = 63 Controls, n = 69
Calcium 2.37 (2.34–2.39) 2.34 (2.32–2.37) 0.154
Phosphate 1.13 (1.09–1.17) 1.05 (1.01–1.10) 0.011
Calcium × phosphate 2.67 (2.58–2.77) 2.47 (2.36–2.57) 0.005
https://doi.org/10.1371/journal.pone.0202282.t002
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0.01mg/mL but not at 0.005mg/mL. Serial step-up concentrations from 0.005mg/mL identified
a lower-limit of detection of 0.008mg/mL (S1 Fig).
The images show the micro-crystals identified by arrows. Below 0.008mg/mL the crystals
were not seen. The experiment was run twice and produced the same result on each occasion.
In the case-control study no micro-crystals were identified in micrographs from any patient
(affected or unaffected). An example from one patient with aortic stenosis is shown in Fig 1,
which shows the red blood cells, but no micro-crystals and contrasts with a healthy volunteer
sample to which synthetic micro-crystals were added.
Discussion
The results show that scanning electron microscopy imaging methods used in the detection of
calcium phosphate hydroxyapatite micro-crystals on aortic valve tissue can be modified to
detect synthetic micro-crystals added to the blood of healthy volunteers. In spite of finding an
increased concentration of calcium phosphate in the serum of patients with aortic stenosis, no
circulating micro-crystals were identified.
Epidemiological studies show positive associations between the serum levels of calcium,
phosphate, the calcium phosphate product and the presence and severity of calcific aortic valve
stenosis [7–10]. Our results are consistent with these findings, showing a statistically signifi-
cantly higher level of calcium phosphate in cases of aortic stenosis than controls without aortic
stenosis. These associations, whilst positive, are insufficient in size, with odds ratios for aortic
stenosis of about 1.5 per 0.1mg/dL increase in serum marker, to be worthwhile screening tests
for the disorder [11], justifying the search for other screening markers.
It is known that increasing levels of calcium and phosphate, within the physiological range,
induce calcification of valvular interstitial cells in vitro [12]. Serum is a metastable solution
with respect to calcium phosphate precipitation. Once started, calcification proceeds rapidly in
the presence of calcifiable templates such as collagen, elastin, and cell debris, in the same way
as crystals grown from a saturated solution of constituent ions in the presence of a seed crystal
[13,14]. The absence of micro-crystals in the blood of any of the 63 patients with aortic steno-
sis, in our study, suggests that these crystals are initially formed in the valvular tissue and once
formed are not released in the circulation. However, the positive association between serum
calcium phosphate and aortic stenosis in our study, supported by others [7–9], leaves open the
possibility that extra calcium and phosphorus in circulation may potentiate the growth of the
mineral, once established in the valvular tissue. Pharmacological methods for reducing serum
calcium or phosphate or both may therefore have a role in preventing the progression, if not
the initiation, of the disorder.
Circulating inhibitors of calcification, may explain the lack of blood-borne micro-crystals.
Fetuin-A, for example, is a liver-derived protein that is a potent circulating inhibitor of
calcification [15]. It has been shown, in vitro, to inhibit spontaneous calcium phosphate
hydroxyapatite formation from solutions supersaturated in calcium and phosphate [16] by
rapid formation of soluble colloidal fetuin-A calcium phosphate complexes [17,18]. Such
inhibitors may prevent precipitation of calcium phosphate even when serum levels are high.
There is also a view that aortic valve calcification is not simply a physico-chemical process but
an active one that involves in situ transition of valve interstitial cells to osteoblast-like bone
forming cells [19] or transition of valve endothelial cells to mesenchymal cells with matrix
effects giving rise to local calcium phosphate deposition or formation within the tissue itself
[20].
It is possible that our method for detecting micro-crystals was insufficiently sensitive, with
a lower detectable concentration limit of 0.008mg/mL. The synthetic calcium phosphate
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Fig 1. Scanning electron micrograph of red blood cells. (a) from healthy volunteer, mixed with synthetic calcium phosphate
micro-crystals which are visible and indicated by arrows and (b) of red blood cells in a blood sample from a patient with aortic valve
stenosis with no micro-crystals visible. Scale Bar = 10μm.
https://doi.org/10.1371/journal.pone.0202282.g001
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micro-crystals which we used in the validation study had similar size (about 200nm) to the cal-
cium phosphate particles previously identified on valvular tissue [3] and these were easily iden-
tified, so we believe it is likely that scanning electron microscopy, which has a lower limit of
resolution of about 1nm, would have detected crystals in the blood had they been present. Our
method of sample preparation was tailored to detecting the calcified particles previously iden-
tified on aortic valve tissue, rather than calciprotein particles which exist as colloid in solution
and require much stronger and longer separation methods. [21]
Conclusion
Calcium phosphate crystals are a fundamental particle in the development of aortic valve ste-
nosis and can be demonstrated using scanning electron microscopy. The results of our study
indicate that in spite of higher levels of serum calcium and phosphate in patients with aortic
stenosis, precipitation of calcium phosphate particles does not occur freely in the blood.
Supporting information
S1 Fig. Results of validation study showing concentrations of synthetic hydroxyapatite
micro-crystals added to healthy volunteer blood samples and scanning electron micros-
copy images. Hydroxyapatite particles are indicated by the arrow. Scale bar = 10μm.
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